R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

a hand sprouts money plant a man plucks a coin from

Grants for funding pharmaceutical research: Growing without ...

Whilst equity investment is likely to be central to the funding strategy of many early-stage biotechs, grant funding can be a very useful alternative.

R&D

Precision medicine - closing the loop: What happens after th...

We often talk about diagnostics as the gateway to precision medicine. But what happens before and after the test?

R&D

magnifying glass over a figure in red amid many in black

Novel study designs for rare diseases

Developing treatments for rare diseases poses many unique challenges that cannot be addressed by traditional study designs.

R&D

Trajectory-based diagnostics enable early intervention in pr...

Diagnostic testing in modern medicine remains largely episodic and threshold-based.

R&D

Q2 clinical trials round-up: April to June 2025

The second quarter of 2025 has seen a surge of clinical trial activity across the pharmaceutical and biotech landscape.

R&D

Changing Faces – Pharma and biotech hires for June 2025

Read on for some of the key appointments of last month. Bristol Myers Squibb adds two executive leaders.